When studying cysteinyl proteases in general and caspases in particular, it is generally accepted that a reaction buffer must contain a reducing agent to prevent essential cysteinyl groups from spontaneous oxidation. Dithiothreitol (DTT) and β-mercaptoethanol (β-MCE) are 2 of the most broadly used reducing agents. While screening a library of small molecules against caspase-3, the authors have found that the nature of the reducing agent used, DTT or β-MCE, dramatically affects screening results and leads to identification of nonoverlapping hits. Screening in DTT-containing buffer revealed few novel classes of small molecules that selectively and reversibly inhibit caspase-3 but failed to identify isatin sulfonamides recently found to be potent and selective caspase-3 inhibitors (false negatives). On the other hand, screening in the presence of β-MCE failed to identify a series of hit compounds, 1,3-dioxo-2,3-dichloro-1H-pyrrolo[3,4-c]quinolines, discovered with DTT, whereas isatin sulphonamides in these conditions exhibited strong caspase-3 inhibition. In this work, the authors show that thiol-containing reducing agents can affect catalytic activity of caspase-3 and modify its thermostability in a redox-potentialindependent manner. The authors speculate that the differential structural modifications of caspase-3 seen with different reducing agents represent structurally different caspase-3 conformations and are responsible for its differential sensitivity to small molecules of different chemotypes. Hence, selection of the reducing agent may dramatically affect the quality of highthroughput screening campaigns. (Journal of Biomolecular Screening 2006:694-703) Journal of Biomolecular Screening 11(6); 2006 www.sbsonline.org 695 FIG. 8. Three-dimensional structure of caspase-3 active site complexed with either Ac-DEVD-CHO (A) or GSK-31 (B). Chain A and chain B amino acid residues located in the 5 Å vicinity of the corresponding ligand (yellow) are colored in magenta and blue, respectively.
INTRODUCTION
A MAJOR BIOCHEMICAL PATHWAY involved in apoptosis, also known as programmed cell death, includes a cascade of proteases that activate downstream family members by cleavage of a specific peptide bond next to an aspartic acid moiety. The downstream caspases are responsible for breakdown or cleavage of key cellular substrates that are required for normal cellular function, including structural proteins in the cytoskeleton and nuclear proteins such as DNA repair enzymes.
Caspases are found practically in all organisms from Caenorhabditis elegans to humans. 1 At least 12 of the caspases have been cloned (caspases 1 through 10, 13, and 14). 2, 3 Two murine caspases, 11 and 12, have no known human counterpart. Two major functionally distinct groups of the caspases are currently recognized as participating in either inflammation or apoptosis. Caspases share a high degree of amino acid sequence similarities, 4 including a cysteinyl in their active site that is essential for their proteolytic activity. Based on their functionality, caspases have been subdivided into 2 subfamilies: those involved in inflammation (caspases 1, 4, 5, 11, 12, 13, and 14) and in apoptosis (caspases 2, 3, 6, 7, 8, 9, and 10) . Based on their relative position in the death signaling pathway, the subfamily of apoptosis-related caspases has been further subdivided into 2 groups: initiator caspases (caspases 2, 8, 9, and, probably, 10) and executioner (or effector) caspases (3, 6, and 7) . 5 Activation of caspase-3 is a key event integrating upstream death signals into final execution of the cell death. This makes caspase-3 an interesting therapeutic target, and the search for caspase-3 inhibitors is an active focus of many drug development programs. [6] [7] [8] High-throughput screening (HTS) of diverse small-molecule libraries has resulted in identification of small-molecule caspase-3 inhibitors belonging to a limited number of chemical types, isatin sulfonamides 9 and anilinoquinazolines. 8 We have described a few new classes of capase-3 inhibitors discovered in our focused library of protease inhibitors. [10] [11] [12] [13] [14] A major weakness of HTS strategies is the necessity for simplified assay conditions, including the use of recombinant proteins as screening targets. Among others, a major issue in HTS campaigns is the relatively high numbers of false positives and false negatives within a single assay system. It is well known among screeners that different methods and assays may produce nonoverlapping hits (positive in one assay and negative in other). The reason for such behavior is not always well understood, and substantial follow-up work is needed to discriminate robust hits from false positives for subsequent development.
As caspase activity strictly depends on reduced active site cysteinyl, the screening buffer always contains a reducing agent to protect the cysteinyl from oxidation. We have noticed that various published assays for detection of caspase inhibition include either dithiothreitol (DTT) or β-mercaptoethanol (β-MCE) in the reaction buffer, but we failed to find a rationale for the choice of reducing agent. In this article, we show that DTT and β-MCE differentially affect caspase-3 and strictly define its sensitivity to different small-molecule inhibitor chemotypes.
MATERIALS AND METHODS

Reagents
Recombinant full-length caspase-3 expressed in Escherichia coli was purchased from Upstate USA (Charlottesville, VA). Caspase-3 substrate, Ac-DEVD-AMC, was from Bachem (King of Prussia, PA). All reducing agents were acquired from Sigma-Aldrich. All other reagents were research grade.
Enzyme assay
The assay buffer contained 2 mM EDTA, 0.1% Chaps, 20 mM HEPES pH 7.4, and 5 mM of a reducing agent (as indicated in the text). In a typical experiment, 30 µL of the substrate, 50 µM Ac-DEVD-AMC, and 30 µL of 0.7 U/µL caspase-3 were added to the microplates. The enzymatic activity of the caspase-3 was measured at ambient temperature by registering the timedependent accumulation of the fluorescent product, methylcoumarine, which forms during cleavage of the fluorogenic substrate, Ac-DEVD-AMC. Caspase-3 was prepared freshly from a frozen stock by diluting with the assay buffer.
A BiomekFX Assay Work Station (Beckman Coulter, Fullerton, CA) was used for plate formatting and reagent distributions. Fluorescence measurements were performed in Corning black 384-well plates using a VICTOR 2 V 96/384 multilabel plate reader (PerkinElmer Life Sciences, Boston, MA) at λ ex = 360 nm and λ em = 460 nm (top readout).
Caspase-3 thermo inactivation
Thermo inactivation of caspase-3 was performed at 80 °C by mixing equal volumes of ice-cold enzyme with preheated (80 °C) assay buffer containing either no reducing agent or one of the redox components tested, 5 mM DTT or 5 mM β-MCE, and incubating these mixtures for indicated times in a 80 °C water bath. After the incubation, the samples were transferred onto an ice chiller.
Redox potential measurements
Redox potentials were measured at 20 °C using an Orion 91-79 ORP Triode™ Electrode (Thermo Electron Corporation, Waltham, MA) in 5-mM water solutions of the redox agents.
Rendering caspase-3 amino acid residues in contact with small-molecule inhibitors
Structures of caspase-3 complexes with either Ac-DEVD-CHO or isatin sulfonamide (6058 and 13604, respectively) were retrieved from the Molecular Modeling Database 15 and visualized in a 3-dimensional (3D) view with Cn3D 4.1. 16 Determination of ligand proximity to amino acids (distance less than 5 Å) in α and β chains was performed using the "select by distance" function of Cn3D.
Data fitting and statistics
All curve fittings were performed with Prism 4 software (GraphPad, San Diego, CA) using built-in equations.
RESULTS
Comparison of inhibitory activity of CD-001-0011 and isatin sulfonamide
Despite a very good detection window (Z′ > 0.8), 17 our protease-focused library 14 screening campaign against caspase-3 failed to detect recently discovered caspase-3 inhibitor 7,9 (compound 31, 9 GSK-31) of isatin sulfonamide series ( Fig. 1 , open triangles). At the same time, the screening campaign produced hits representing at least 11 new chemotypes. 14 One of the chemotypes, pyrroloquinoline-dione sulfonamide, was further used to create a series of structure-activity relationship libraries for lead optimization, which produced a potent (IC 50 ≈ 130 nM) and reversible caspase-3 inhibitor, CD-001-0011 ( Fig. 1B) , capable of preventing apoptosis in cell cultures (Jurkat, NIH-3T3, and SH-SY5Y) as well as in zebrafish. 14 In this study, we have attempted to investigate why our screening campaign failed to detect isatin sulfonamides and yet produced active caspase-3 inhibitors of other chemotypes with antiapoptotic activity in cell-based and whole animal tests. We noticed that unlike our screening campaign, the original work describing isatin sulphonamides 7,9 β-MCE was used as a reducing agent. We decided to test the hypothesis that caspase-3 sensitivity to different inhibitor classes is affected by the substitution of β-MCE for DTT.
We compared potency values, expressed in pIC 50 units, of CD-001-0011, GSK-31, and irreversible caspase-3-selective peptide aldehyde inhibitor, Ac-DEVD-CHO, measured in the presence of either reducing agent as well as in their mixture (Fig. 2) . In these experiments, caspase-3 was diluted with the assay buffers containing, respectively, 5 mM DTT (checkered bars), 5 mM β-MCE (dotted bars), or their mixture (open bars).
Substitution of DTT with β-MCE led to 3 to 4 orders of magnitude decrease in CD-001-0011 potency and 2 orders of magnitude increase in GSK-31 potency (Fig. 2 , compare checkered and dotted bars). When the small-molecule potencies were measured in the presence of both DTT and β-MCE (open bars), the inhibition pattern was consistent with that observed in the presence of DTT alone. In contrast, potencies of the peptide inhibitor, Ac-DEVD-CHO, were practically identical in either of the reducing agents.
Effect of redox compounds on caspase-3 activity and compound potencies
We hypothesized that thio-containing reducing agents could directly interact with the enzyme and thus modify its sensitivity to different small-molecule inhibitor classes. Therefore, effects of a series of redox agents on caspase-3 activity itself and on the potencies of CD-001-0011 and GSK-31 were studied. Figure 3 shows caspase-3 activity measured in the presence of different redox agents (a control activity, no reducer added, is taken as 100%). In general, a correlation trend (Pearson r = -0.652, with p = 0.001) was observed between redox potentials of the 5 mM agents and their ability to cause the enzyme activation ( Fig. 3 , inset). For example, oxidized forms of homocysteine, cysteine, and DTT caused substantially less activation (in some cases even inactivation) than their corresponding reduced forms did. However, a few strong reducing agents, lipoic acid and 1,2-butanedithiol, potently inhibited the enzyme, whereas 1,3-benzenedithiol, having approximately equal reducing potential, showed higher activity than could be predicted from the correlation function. Interestingly, glutathione, an endogenous cell cytoplasm component that participates in a control of the intracellular reducing environment, showed no substantial caspase-3 stimulation. Although this observation is in agreement with glutathione's negligible stimulation of caspase-3(-like) activity in lysates of anti-Fas mAB-stimulated Jurkat cells, 18 one cannot exclude rapid oxidation of glutathione under atmospheric conditions as an explanation for this negative finding. As indirect evidence for the rapid spontaneous oxidation of glutathione, we noticed that the redox electrode reading consistently drifted toward positive values when measuring redox potential in 5 mM glutathione buffer solution (data not shown).
Potencies of CD-001-0011 and GSK-31 measured in the presence of different redox substances are shown in no redox compounds and in the presence of either of the following redox agents: 1,4-butanedithiol, 1,2-benzene dithiol, β-MCE, 1,3-benzenedimethanthiol, 1,4-benzenedimethanediol, 2,3-dimercapto-1-propanesulfonic acid, and poly(1,4-phenylene sulfide). In contrast, CD-001-0011 produced 1 to 2 orders of magnitude lower inhibition potency in the presence of these redox agents and substantially more potent inhibition in the presence of DTT, lipoic acid, and 1,2 butanedithiol, the very same reducing agents that inhibited caspase-3 activity (Fig. 3) . The inhibitor potencies in the presence of different redox agents did not seem to correlate either with the redox potentials of the agents (Fig. 4B) or with caspase-3 activity (Fig. 4C) . Although these data strongly indicate that thiol-containing reducing agents can substantially modify caspase-3 enzymatic activity as well as its sensitivity to different nonpeptide inhibitors, the molecular mechanisms of such effects are still to be elucidated.
Effect of DTT and β β-MCE on enzymatic parameters of caspase-3
To indirectly assess a possibility that DTT and β-MCE differentially affect caspase-3 itself, we compared their effect on the Michaelis constant, K M , and maximal activity, V max , of caspase-3 ( Table 1) . 
FIG. 3.
Effect of different redox compounds on caspase-3 activity normalized to a control (no redox compound added). The compounds are positioned on the graph's x scale in accordance with their measured redox potentials from the left (highly reducing) to the right (highly oxidizing). In the inset, a correlation between caspase-3 activity and corresponding redox potentials is shown (both the enzyme activity and redox potentials were measured at a redox agent concentration of 5 mM). Dashed lines show the 90% confidence area of the regression. In these experiments, we measured substrate conversion rates as a function of the substrate concentration in the absence or presence of the redox agents in the buffer. The data showed that while 5 mM DTT did not affect K M , β-MCE produced a statistically significant increase in the substrate affinity to the enzyme. Both reducers demonstrated a substantial increase in the maximal conversion rates, V max , with DTT causing almost twice as high maximal stimulation as β-MCE.
The increase in the enzyme activity, V max , in the presence of the reducing agents can be attributed to either an increase in the number of active caspase-3 molecules, an effect compatible with an oxidation protection, or an increase in the conversion (catalytic) rate of each enzyme molecule, an effect conforming to the enzyme conformational modification. A lower value of V max in β-MCE as compared to DTT seems to indicate that DTT is a substantially better antioxidant than β-MCE is, and hence it cannot fully prevent caspase-3 oxidation, at least at the reducer concentration of 5 mM. If this is the case, one could have expected that the difference between enzyme V max values would diminish with an increase in the reducer concentrations. The concentration curves of the enzyme activation with both DTT and β-MCE showed a saturation pattern (data not shown). Both reducers activated caspase-3 with practically identical EC 50 values, whereas DTT produced substantially higher maximum activation, A max ( Table 2) . If the role of the reducing agents, as mentioned above, were to merely protect caspase-3 from spontaneous oxidation, one would expect an increase in caspase-3 activity to the same maximal plateau level irrespective of the reducing agent used as long as its redox potential is higher than that of the thio group to be protected. At the same time, the EC 50 values of such activation curves would be expected to differ for different reducers as a function of their reduction potentials. The data in Table 2 show that despite the redox potential differences between DTT and β-MCE (-215 mV and -154 mV, respectively, measured at a reducer concentration of 5 mM), the EC 50 values for the 2 reducers are close to each other. These tend to support the argument that additional mechanisms other than protection of the active site cysteinyl from spontaneous oxidation may be involved in the reducing agents' caspase-3 activation.
To establish a mechanistic relationship between the caspase-3 stimulation effect of the reductants and inhibition effect of the small molecules, Ac-DEVD-CHO, CD-001-0011, and GSK-31, we measured the reducing agent concentration-dependent activation of caspase-3 in the presence of different concentrations of the inhibitors (Fig. 5) . Neither DTT nor β-MCE could overcome the caspase-3 inhibition by either inhibitor. All 3 inhibitors decreased the maximal reducer-induced caspase-3 stimulation, A max , and the reductants' "affinity" to caspase-3 (increases in EC 50 ) in a concentration-dependent manner (Fig. 6) . If one were to assume that the role of the reducing agents was merely to prevent enzyme sulfhydryl groups from their spontaneous oxidation, one should expect the inhibitors to affect A max with no changes in EC 50 . Recently, it was suggested 19 that there is a possibility for some compounds to catalizing oxidation of DTT and thus effectively diminishing a concentration of its reduced form necessary for the enzyme thiol protection. In our experiments, we have seen that in the presence of CD-001-0011, DTT but not β-MCE slowly oxidizes (data not shown). We have also failed to detect any oxidation of either of the 2 reducers by both GSK-31 and tetrapeptide aldehyde. This led us to propose that in addition to their antioxidant activity, the reducers activate caspase-3 through a site that might or might not be different from the site of the small-molecule inhibitor action. Interestingly, the tetrapeptide inhibitor acted similarly to the nonpeptide inhibitors in both reducing A max and increasing EC 50 . It was shown that in the presence of a peptide substrate, caspase-3 undergoes a conformational change leading to increased accessibility of its active site thiolate anion to oxidation by hydrogen peroxide. 20 One can presume that the reversible caspase-3 inhibitors might also induce conformational changes in caspase-3, which lead to a reduced affinity of its activation site(s) to the reductants.
Effect of the reducing agents on caspase-3 thermoinactivation
To further elucidate potential conformational changes that the reductants could be inducing in caspase-3, we used an indirect approach to examine enzyme sensitivity to thermoinactivation. Protein thermoinactivation kinetics was broadly used to assess conformational stability of proteins upon modification of their amino acid residues. 21 We measured kinetics of irreversible enzyme inactivation at 80 °C in the presence of the reducers, DTT or β-MCE. The irreversible thermoinactivation of the enzyme was assessed by exposing it to 80 °C for varying time intervals with subsequent transfer to a bath with melting ice. The residual enzyme activity was measured at room temperature (Fig. 7) .
Both reducing agents substantially slowed down caspase-3 thermoinactivation rates compared to "no reducer" conditions. In the presence of DTT, caspase-3 showed substantially higher tolerance than with β-MCE (Fig. 7) . Unexpectedly, very brief enzyme heating in the presence of DTT produced statistically significant irreversible activation of caspase-3 (negative values on the percentage inhibition scale), which supports a mechanism whereby DTT induces a different conformer than that in the presence of β-MCE. These data corroborate the hypothesis that caspase-3 has different conformational characteristics in different reducing agents. It seems reasonable to propose that the reductant-induced caspase-3 conformations are responsible for differential sensitivity to small-molecule inhibitors of different chemical classes, with DTT conformation having higher maximal enzymatic activity and displaying a high affinity to CD-001-0011 and low affinity to GSK-31, whereas β-MCE conformation had much higher selectivity toward GSK-31. Notably, both redox conformations have identical affinities toward the peptide inhibitor.
DISCUSSION
Both DTT and β-MCE are the most commonly used reducing agents in assay buffers to prevent enzymes from inactivation through spontaneous oxidation of obligatory cysteinyl residues. It was shown that oxidation of Cys-285 in caspase-3 with hydroperoxide 20 or diamide 18 or its nitrosylation with NO donors such as S-nitrosoglutathione, BF4NO, and spermine-NO 22, 23 leads to the enzyme inactivation. This inhibition could at least partially be reversed by DTT, and the maintenance of the reducing environment by DTT was suggested to preserve caspase-3 in its active state. With some exceptions, our data, presented in Figure 4 , supports such a relation between the agents' redox potentials and caspase-3 activity. However, the ability of some highly reducing thiol-containing agents, such as lipoic acid and 1,2-butanedithiol, to inhibit caspase-3 suggests that thio compounds could also directly interact with caspase-3 and change its catalytic characteristics. Indeed, it was shown that disulfiram (tetraethylthiuram disulfide) reacted with essential sulfhydryl groups of D-amino acid oxidase 24 or caspase-1, 25 forming mixed disulfides through thiol-disulfide exchange. Such reactions led to allosteric enzyme inhibition.
It was hypothesized that the use of DTT as a reducing agent could produce false-positive hits due to interaction of the compounds with DTT and production of reactive oxygen species, which in turn inhibit caspase. These conclusions are based on studies of caspase-3-selective inhibitors, dihydropyrimido [1,2a] indolones, discovered during an HTS campaign. 19 The authors showed that the compounds were oxidizing DTT and exhibited high caspase-3 inhibition potency in DTT-containing media, which diminished when DTT was substituted for glutathione (GsH). In agreement with our data, isatin sulfonamides were also shown to lose their activity in DTT, whereas Ac-DEVD-CHO potency did not depend on the presence of either reducing agent. A conclusion has been made that the inhibition of caspase-3 by the compounds was due to the generation of a reactive oxygen species in a redox reaction between dihydropyrimido[1,2a]indolones and DTT. Although this is an attractive explanation of irreversible inhibition caused by dihydropyrimido [1,2a] indolones, this mechanism fails to explain 3 phenomena we observed: 1) reversibility of caspase-3 inhibition by CD-001-0011, 14 2) diminished isatin inhibition potency in the presence of DTT while the tetrapeptide potency stayed the same despite the fact that isatin is supposed to bind to the same active site as the tetrapeptide, and 3) selectivity of the observed inhibition; it is unlikely that the sulfhydryl group of caspase active sites have such huge differences (orders of magnitude) in their susceptibility to peroxide without undergoing conformational changes.
As we have shown in this work, DTT and β-MCE differentially affect caspase-3 catalytic activation ( Table 1) , thermostability (Fig. 7) , and its sensitivity to small-molecule inhibitors of different chemical classes (Fig. 2) . We suggest that DTT and β-MCE induce different structural rearrangements of caspase-3, with a DTT conformer being sensitive to compounds of the CD-001-0011 series and a β-MCE conformer being sensitive to isatin sulfonamides. Both conformers seem to have identical sensitivity to Ac-DEVD-CHO.
Molecular modeling based on the x-ray structure of GSK-31/ caspase-3 cocrystals showed that it covalently binds to the same Cys of the caspase-3 active site 9 as the tetrapeptide aldehyde does. 26 Figure 8 shows amino acid residues located in the 5 Å vicinity of corresponding caspase-3 inhibitor. These are the most probable amino acid candidates participating in the interaction with the ligands. A comparison of amino acid clusters participating in interactions with either Ac-DEVD-CHO or GSL-31 is shown below. It appears that both chain A and chain B participate in forming the binding site for each of the 2 ligands. The colored amino acid residues located at distances of up to 5Å from the ligand were determined from the X-ray 3D structures, 1PAU and 1GFW, in a pdb database. 27, 28 One can see that a major pattern of the amino acids surrounding the tetra peptide aldehyde are mainly preserved in the binding site for GSK-31.
Inhibition of caspase-3 with CD-001-0011, though reversible, is not competitive, 14 indicating that the binding site for this class of small molecules is allosteric relative to the caspase-3 active site and that one could assume that the DTT and β-MCE enzyme conformers differ in their allosteric 1,3-dioxo-2,3dichloro-1H-pyrrolo[3,4-c]quinolines (DDPQ)-binding site but are more or less similar in their substrate binding sites. However, this cannot explain why isatin sulfonamide, which was shown to bind to the same substrate site, 9 loses its activity in the presence of DTT. We must point out, however, that the GSK-31/caspase-3 cocrystals were grown in 10 mM Cyscontaining buffer. 7 We could not find published structures of such complexes in crystals grown out of DTT or β-MCE-containing media, and hence it is not clear if the isatin sulfonamide could also bind to caspase-3 in the presence of DTT. Additional work to obtain caspase-3 crystals from buffers containing DTT and β-MCE as well as their cocrystals with CD-001-0011 and GSK-31 is required to distinguish the 2 conformers and the binding mode of these inhibitors.
We also showed that different sulfhydryl-containing reducing agents can activate or inactivate caspase-3 ( Fig. 3) as well as control the enzyme sensitivity toward different small-molecule inhibitor classes ( Fig. 4) without an obvious correlation with their redox potentials. Both DTT and β-MCE activate caspase-3 by increasing its catalytic rate (V max ), with DTT being twice as effective as β-MCE. Caspase-3 was also more stable to thermoinactivation in the presence of DTT, and its short-term exposure to high temperatures in the presence of DTT even led to increased enzyme activity. These data support the idea that DTT and β-MCE differentially affect caspase-3 characteristics, possibly through inducing different conformational changes in the enzyme. Interestingly, unlike CD-001-0011 or GSK-31, the irreversible tetrapeptide aldehyde inhibitor, Ac-DEVD-CHO, was equipotent for the 2 proposed enzyme conformational states (Fig. 2) .
Despite the opposite caspase-3 inhibition potency trend in the presence of either of the 2 reducing agents, isatin sulfonamides, 7 DDPQs, 14 and anilinoquinazolines 8 are active in preventing cell apoptosis, albeit at much higher concentrations than their IC 50 values measured with the isolated enzyme. Taking into consideration that in the cell-based assays, neither DTT nor β-MCE is present, the antiapoptotic activity of these compounds attests to their real effects on caspase-3 activity (true positive inhibitors). At the same time, either of them might be missed during HTS campaigns, depending on the choice of the reductant present (false-negative inhibitors) in the assay buffer.
We conclude that although use of a reducing agent is sometimes necessary in screening assays, their use may invoke an additional dimension into the multivariable space of a screening protocol that can strongly affect the behavior of a therapeutic target under investigation. Our data show that this factor should be thoroughly considered when developing assay protocols so that one can identify potential sources of false-positive and, more important, false-negative hits. Conformational plasticity of isolated recombinant protein therapeutic targets, which can be affected by "unnatural" assay environments, presents a challenge as their pharmacological profiles could be substantially different from that of a native protein in physiological environments. In this respect, potential sources of external influence (such as the nature of the reducing agent) should be taken into consideration for screening purposes as well as for follow up of pharmacological profiling of discovered hits.
